Figure 2.

Expression of IL-17 in breast cancer. (a) to (c), (d) to (f) Consecutive sections from two patients stained for (a), (d) IL-17 and (b), (e) the CD68 macrophage marker. (c), (f) A further consecutive section showing the staining obtained when the IL-17-specific antibody was preincubated with a specific neutralising peptide. (d) Of interest, in one out of 19 patients studied there were occasional areas of tumour (T) that stained specifically with the anti-IL-17 antibody.